Royal Bank of Canada Increases Stock Position in uniQure N.V. $QURE

Royal Bank of Canada raised its position in uniQure N.V. (NASDAQ:QURE) by 26.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 107,888 shares of the biotechnology company’s stock after buying an additional 22,248 shares during the period. Royal Bank of Canada owned approximately 0.17% of uniQure worth $1,763,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in QURE. China Universal Asset Management Co. Ltd. grew its holdings in uniQure by 5.5% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,150 shares of the biotechnology company’s stock worth $243,000 after acquiring an additional 533 shares in the last quarter. Arizona State Retirement System lifted its holdings in uniQure by 6.0% in the fourth quarter. Arizona State Retirement System now owns 11,141 shares of the biotechnology company’s stock worth $267,000 after acquiring an additional 627 shares during the last quarter. Ensign Peak Advisors Inc boosted its position in uniQure by 21.7% during the 4th quarter. Ensign Peak Advisors Inc now owns 3,650 shares of the biotechnology company’s stock valued at $87,000 after purchasing an additional 650 shares during the period. CIBC Private Wealth Group LLC acquired a new position in shares of uniQure during the third quarter valued at $50,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in uniQure by 42.7% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,027 shares of the biotechnology company’s stock worth $72,000 after purchasing an additional 906 shares during the last quarter. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Stock Performance

QURE stock opened at $47.38 on Wednesday. The firm has a 50 day simple moving average of $42.10 and a 200 day simple moving average of $28.21. uniQure N.V. has a 52 week low of $8.73 and a 52 week high of $71.50. The stock has a market cap of $3.29 billion, a P/E ratio of -11.82 and a beta of 0.93. The company has a debt-to-equity ratio of 0.15, a quick ratio of 10.01 and a current ratio of 10.01.

uniQure (NASDAQ:QURE) last released its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported ($1.22) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.40). The company had revenue of $5.84 million during the quarter, compared to analyst estimates of $5.45 million. uniQure had a negative net margin of 1,350.73% and a negative return on equity of 111.96%. During the same quarter in the prior year, the company posted ($0.69) EPS. Research analysts anticipate that uniQure N.V. will post -3.74 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Wells Fargo & Company increased their price target on uniQure from $60.00 to $75.00 and gave the stock an “overweight” rating in a research note on Thursday, July 30th. Cantor Fitzgerald raised uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 price target on the stock in a report on Wednesday, June 17th. Royal Bank Of Canada upped their price objective on shares of uniQure from $35.00 to $65.00 and gave the company an “outperform” rating in a research note on Thursday, June 18th. Wall Street Zen raised shares of uniQure from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, Wolfe Research upgraded shares of uniQure from a “peer perform” rating to an “outperform” rating and set a $65.00 price target on the stock in a report on Wednesday, July 29th. Thirteen analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, uniQure currently has an average rating of “Moderate Buy” and an average target price of $65.00.

Insider Transactions at uniQure

In other uniQure news, Director Madhavan Balachandran sold 11,685 shares of the business’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $45.06, for a total value of $526,526.10. Following the completion of the sale, the director directly owned 43,254 shares of the company’s stock, valued at $1,949,025.24. The trade was a 21.27% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Walid Abi-Saab sold 30,000 shares of the stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $46.42, for a total transaction of $1,392,600.00. Following the transaction, the insider owned 148,235 shares in the company, valued at approximately $6,881,068.70. This trade represents a 16.83% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 388,229 shares of company stock valued at $16,817,099 in the last quarter. Corporate insiders own 4.65% of the company’s stock.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno?associated viral (AAV) vector platform, the company designs single?dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.